This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

DATE OF RELEASE/EXPIRATION

This activity was released on October 24, 2022 and is valid until October 24, 2023. Requests for credit must be made no later than October 24, 2023

TARGET AUDIENCE

The target audiences for the proposed HCP activity are allergists, dermatologists, immunologists, specialty NPs and PAs,

STATEMENT OF NEED/PROGRAM OVERVIEW

People from racially and ethnically diverse populations with moderate-to-severe atopic dermatitis (AD) face socioeconomic and care inequities that impair their access to optimal care for AD and its comorbidities. In addition, topical corticosteroids and unapproved immunosuppressants are often relied upon to treat moderate-to-severe AD, delaying the evidence-based use of more-effective targeted treatments.

Join a panel of diverse allergy and dermatology specialists, patients, and representatives from the Asthma and Allergy Foundation of America (AAFA) for a series of CME activities designed to share strategies that maintain long-term control across the lifespan of AD, from pediatric to adulthood, while ensuring access and care equity for diverse racial and ethnic patient populations. Expert panelists will address gaps in therapy initiation and long-term efficacy and safety, while reviewing experiences with current therapies for moderate-to-severe AD. The education will also emphasize the systemic and T2-driven nature of AD, along with the need for multidisciplinary care.

Session 1, “Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations,” will highlight the unique challenges that people from diverse racial and ethnic groups face when attempting to access care, obtain a diagnosis, and receive holistic care that addresses AD and any associated comorbidities.

Session 2, “Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library,” will guide clinicians to align therapeutic decisions to clinical endophenotypes in patients of different age groups and races. Panelists will also review evidence-based treatment recommendations to achieve long-term disease control, along with strategies to encourage shared decision-making with patients.

Do you have patients who could benefit from related education on the recognition and treatment of AD? Direct your patients to MedLive.com to access the patient-education activity, “It Isn’t Just Skin: The Ins and Outs of Moderate-to-Severe Atopic Dermatitis.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Drawing from examples in other diseases, such as asthma, summarize strategies to enhance access to AD care for people from diverse populations.
• Summarize the impacts of age, race, and ethnicity on the presentation of AD and the influence of underlying inflammatory pathways on therapeutic decisions
• Engage patients with moderate-to-severe AD and their caregivers in shared decision-making to set treatment expectations, define success, and make timely therapeutic changes to facilitate long-term remission

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 75 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Dr. Jonathan Silverberg MD, PhD, MPH Professor, Director of Clinical Research, Director of Patch Testing George Washington University School of Medicine and Health Sciences Washington, District of Columbia	Consulting Fee: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, Union Speakers’ Bureau: AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme Contracted Research (grants to institution): Galderma, Pfizer Stock Shareholder: Arcutis, Eli Lilly, Pfizer
Dr. Andrew Alexis, M.D. MPH Vice-Chair for Diversity and Inclusion Department of Dermatology Professor of Clinical Dermatology Weill Cornell Medical College, Cornell University	Consulting Fee: AbbVie, Allergan, Almirall, Amgen, Arcutis, Bausch Health, Beiersdorf, Bristol-Myers Squibb, Cutera, Dermavant, Eli Lilly, Galderma, Janssen, Leo, L’Oreal, Ortho, Pfizer, Sanofi-Regeneron, Sol-Gel, Swiss American, UCB, VisualDx, Vyne Contracted Research (funds to institution): AbbVie, Almirall, Amgen, Arcutis, Bristol-Myers-Squibb, Cara, Castle, Dermavant, Galderma, Leo, Novartis, Valeant (Bausch Health), Vyne Speakers’ Bureau: Bristol-Myers Squibb, Pfizer, Regeneron, Sanofi-Genzyme
Sanaz Eftekhari Vice President, Corporate Affairs and Research Asthma and Allergy Foundation of America	Nothing to disclose
Christopher Aviles Adult with severe eczema	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Carole Drexel	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Eve Wilson	Nothing to disclose
Caroline Laurendeau	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

DATE OF RELEASE/EXPIRATION

This activity was released on October 24, 2022 and is valid until October 24, 2023. Requests for credit must be made no later than October 24, 2023

TARGET AUDIENCE

The target audiences for the proposed HCP activity are allergists, dermatologists, immunologists, specialty NPs and PAs,

STATEMENT OF NEED/PROGRAM OVERVIEW

People from racially and ethnically diverse populations with moderate-to-severe atopic dermatitis (AD) face socioeconomic and care inequities that impair their access to optimal care for AD and its comorbidities. In addition, topical corticosteroids and unapproved immunosuppressants are often relied upon to treat moderate-to-severe AD, delaying the evidence-based use of more-effective targeted treatments.

Join a panel of diverse allergy and dermatology specialists, patients, and representatives from the Asthma and Allergy Foundation of America (AAFA) for a series of CME activities designed to share strategies that maintain long-term control across the lifespan of AD, from pediatric to adulthood, while ensuring access and care equity for diverse racial and ethnic patient populations. Expert panelists will address gaps in therapy initiation and long-term efficacy and safety, while reviewing experiences with current therapies for moderate-to-severe AD. The education will also emphasize the systemic and T2-driven nature of AD, along with the need for multidisciplinary care.

Session 1, “Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations,” will highlight the unique challenges that people from diverse racial and ethnic groups face when attempting to access care, obtain a diagnosis, and receive holistic care that addresses AD and any associated comorbidities.

Session 2, “Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library,” will guide clinicians to align therapeutic decisions to clinical endophenotypes in patients of different age groups and races. Panelists will also review evidence-based treatment recommendations to achieve long-term disease control, along with strategies to encourage shared decision-making with patients.

Do you have patients who could benefit from related education on the recognition and treatment of AD? Direct your patients to MedLive.com to access the patient-education activity, “It Isn’t Just Skin: The Ins and Outs of Moderate-to-Severe Atopic Dermatitis.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Drawing from examples in other diseases, such as asthma, summarize strategies to enhance access to AD care for people from diverse populations.
• Summarize the impacts of age, race, and ethnicity on the presentation of AD and the influence of underlying inflammatory pathways on therapeutic decisions
• Engage patients with moderate-to-severe AD and their caregivers in shared decision-making to set treatment expectations, define success, and make timely therapeutic changes to facilitate long-term remission

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Dr. Jonathan Silverberg MD, PhD, MPH Professor, Director of Clinical Research, Director of Patch Testing George Washington University School of Medicine and Health Sciences Washington, District of Columbia	Consulting Fee: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, Union Speakers’ Bureau: AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme Contracted Research (grants to institution): Galderma, Pfizer Stock Shareholder: Arcutis, Eli Lilly, Pfizer
Dr. Andrew Alexis, M.D. MPH Vice-Chair for Diversity and Inclusion Department of Dermatology Professor of Clinical Dermatology Weill Cornell Medical College, Cornell University	Consulting Fee: AbbVie, Allergan, Almirall, Amgen, Arcutis, Bausch Health, Beiersdorf, Bristol-Myers Squibb, Cutera, Dermavant, Eli Lilly, Galderma, Janssen, Leo, L’Oreal, Ortho, Pfizer, Sanofi-Regeneron, Sol-Gel, Swiss American, UCB, VisualDx, Vyne Contracted Research (funds to institution): AbbVie, Almirall, Amgen, Arcutis, Bristol-Myers-Squibb, Cara, Castle, Dermavant, Galderma, Leo, Novartis, Valeant (Bausch Health), Vyne Speakers’ Bureau: Bristol-Myers Squibb, Pfizer, Regeneron, Sanofi-Genzyme
Sanaz Eftekhari Vice President, Corporate Affairs and Research Asthma and Allergy Foundation of America	Nothing to disclose
Raelle Brown Patient Participant	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Carole Drexel	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Eve Wilson	Nothing to disclose
Caroline Laurendeau	Nothing to disclose
Lynell Doyle- Parent of child with Eczema	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.